Porins, efflux pumps and multidrug resistance in Acinetobacter baumannii

Journal of Antimicrobial Chemotherapy

Volumn 59, Issue 6, 2007, Pages 1210-1215

  Vila, Jordi ^a   Martí, Sara ^a   Sánchez Céspedes, Javier ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

A. baumannii; Intrinsic resistance; Permeability

Indexed keywords

4',6 DIAMIDINO 2 PHENYLINDOLE; ACRIFLAVINE; AMINOGLYCOSIDE; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; CHLORAMPHENICOL; CIPROFLOXACIN; DAUNORUBICIN; DOXORUBICIN; ERYTHROMYCIN; ETHIDIUM BROMIDE; GENTAMICIN; HOE 33342; MINOCYCLINE; NORFLOXACIN; OFLOXACIN; PORIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RHODAMINE 6G; TETRACYCLINE; TRICLOSAN;

ACINETOBACTER BAUMANNII; BACTERIAL GENE; BACTERIAL INFECTION; BACTERIAL STRAIN; DRUG USE; GENE MUTATION; INTENSIVE CARE UNIT; MULTIDRUG RESISTANCE; NONHUMAN; NUCLEOTIDE SEQUENCE; OPPORTUNISTIC INFECTION; REVIEW;

ACINETOBACTER BAUMANNII; BACTERIAL OUTER MEMBRANE PROTEINS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; P-GLYCOPROTEINS; PORINS;

EID: 34447556772     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl509     Document Type: Review

References (48)

1. Bergogne-Berezin E, Towner KJ. Acinetobacter spp. as nosocomial pathogens: Microbiological, clinical, and epidemiological features. Clin Microbiol Rev 1996; 9:148-65.
2. Biendo M, Laurans G, Lefebvre JF et al. Epidemiological study of an Acinetobacter baumannii outbreak by using a combination of antibiotyping and ribotyping. J Clin Microbiol 1999; 37: 2170-5.
3. Getchell-White SI, Donowitz LG, Groschel DH. The inanimate environment of an intensive care unit as a potential source of nosocomial bacteria: evidence for long survival of Acinetobacter calcoaceticus. Infect Control Hosp Epidemiol 1989; 10: 402-7.
4. Salazar de Vegas EZ, Nieves B, Araque M et al. Outbreak of infection with Acinetobacter strain RUH 1139 in an intensive care unit. Infect Control Hosp Epidemiol 2006; 27: 397-403.
5. Musa EK, Desai N, Casewell MW. The survival of Acinetobacter calcoaceticus inoculated on fingertips and on formica. J Hosp Infect 1990; 15: 219-27.
6. Jawad A, Seifert H, Snelling AM et al. Survival of Acinetobacter baumannii on dry surfaces: Comparison of outbreak and sporadic isolates. J Clin Microbiol 1998; 36: 1938-41.
7. Vila J. Mechanisms of antimicrobial resistance in Acinetobacter baumannii. Rev Med Microbiol 1998; 9: 87-97.
8. Somerville DA, Noble WC. A note on the gram-negative bacilli of human skin. Rev Eur Etud Clin Biol 1970; 15: 669-71.
9. Rosenthal S, Tager IB. Prevalence of gram-negative rods in the normal pharyngeal flora. Ann Intern Med 1975; 83: 355-7.
10. Grehn M, von Graevenitz. A. Search for Acinetobacter calcoaceticus subsp. anitratus: Enrichment of fecal samples. J Clin Microbiol 1978; 8: 342-3.
11. Corbella X, Pujol M, Ayats J et al. Relevance of digestive tract colonization in the epidemiology of nosocomial infections due to multi-resistant Acinetobacter baumannii. Clin Infect Dis 1996; 23: 329-34.
12. Goldstein FW, Labigne-Roussel A, Gerbaud G et al. Transferable plasmid-mediated antibiotic resistance in Acinetobacter Plasmid 1983; 10: 138-47.
13. Ribera A, Roca I, Ruiz J et al. Partial characterization of a transposon containing the tet(A) determinant in a clinical isolate of Acinetobacter baumannii. J Antimicrob Chemother 2003; 52: 477-80.
14. IMP-5, a new integron-borne metallo-β-lactamase gene from an Acinetobacter baumannii nosocomial isolate in Portugal. FEMS Microbiol Lett 2002; 215: 33-9.
15. Ruiz J, Navia MM, Casals C et al. Integron-mediated antibiotic multiresistance in Acinetobacter baumannii clinical isolates from Spain. Clin Microbiol Infect 2003; 9: 907-11.
16. Ribera A, Vila J, Fernández-Cuenca F et al. Type 1 integrons in epidemiologically unrelated Acinetobacter baumannii isolates collected at Spanish hospitals. Antimicrob Agents Chemother 2004; 48: 364-65.
17. Nemec A, Dolzani L, Brisse S et al. Diversity of aminoglycoside-resistance genes and their association with class 1 integrons among strains of pan-European Acinetobacter baumannii clones. J Med Microbiol 2004; 53: 1233-40.
18. Turton JF, Kaufmann ME, Glover J et al. Detection and typing of integrons in epidemic strains of Acinetobacter baumannii found in the United Kingdom. J Clin Microbiol 2005; 43: 3074-82.
19. SIM-1, in a class 1 integron from Acinetobacter baumannii clinical isolates from Korea. Antimicrob Agents Chemother 2005; 49: 4485-91.
20. Gombac F, Riccio ML, Rossolini GM et al. Molecular characterization of integrons in epidemiologically unrelated clinical isolates of Acinetobacter baumannii from Italian hospitals reveals a limited diversity of gene cassette arrays. Antimicrob Agents Chemother 2002; 46: 3665-8.
21. Fournier PE, Vallenet D, Barbe V et al. Comparative genomics of multidrug resistance in Acinetobacter baumannii. PLoS Genet 2006; 2: 62-72.
22. Martí S, Sánchez-Céspedes J, Oliveira E et al. Proteomic analysis of a fraction enriched in cell envelope proteins of Acinetobacter baumannii. Proteomics 2006; 6 Suppl 1: 82-7.
23. Obara M, Nakae T. Mechanisms of resistance to β-lactam antibiotics in Acinetobacter calcoaceticus. J Antimicrob Chemother 1991; 28 791-800.
24. Sato K, Nakae T. Outer membrane permeability of Acinetobacter calcoaceticus and its implication in antibiotic resistance. J Antimicrob Chemother 1991; 26: 35-45.
25. Bou G, Cerveró G, Dominguez MA et al. Characterization of a nosocomial outbreak caused by a multiresistant Acinetobacter baumannii strain with a carbapenem-hydrolyzing enzyme: High-level carbapenem resistance in A. baumannii is not due solely to the presence of β-lactamases. J Clin Microbiol 2000; 38: 3299-305.
26. Fernández-Cuenca F, Martínez-Martínez L, Conejo MC et al. Relationship between β-lactamase production, outer membrane protein and penicillin-binding protein profiles on the activity of carbapenems against clinical isolates of Acinetobacter baumannii. J Antimicrob Chemother 2003; 51: 565-74.
27. Mussi MA, Limansky AS, Viale AM. Acquisition of resistance to carbapenems in multidrug-resistant clinical strains of Acinetobacter baumannii natural insertional inactivation of a gene encoding a member of a novel family of β-barrel outer membrane proteins. Antimicrob Agents Chemother 2005; 49: 1432-40.
28. Gribun A, Nitzan Y, Pechatnikov I et al. Molecular and structural characterization of the HMP-AB gene encoding a pore-forming protein from a clinical isolate of Acinetobacter baumannii. Curr Microbiol 2003; 47: 434-43.
29. Nitzan Y, Pechatnikov, I, Bar-El D et al. Isolation and characterization of heat-modifiable proteins from the outer membrane of Porphyromonas asaccharolytica and Acinetobacter baumannii. Anaerobe 1999; 5: 43-50.
30. Nikaido H. Molecular basis of bacterial outer membrane permeability revisited. Microbiol Mol Biol Rev 2003; 67: 593-656.
31. Walzer G, Rosenberg E, Ron EZ. The Acinetobacter outer membrane protein A (OmpA) is a secreted emulsifier. Environ Microbiol 2006; 8: 1026-32.
32. Tomas MM, Beceiro A, Perez A et al. Cloning and functional analysis of the gene encoding the 33- to 36-kilodalton outer membrane protein associated with carbapenem resistance in Acinetobacter baumannii. Antimicrob Agents Chemother 2005; 49: 5172-5.
33. Siroy A, Molle V, Lemaitre-Guillier C et al. Channel formation by CarO, the carbapenem resistance-associated outer membrane protein of Acinetobacter baumannii. Antimicrob Agents Chemother 2005; 49: 4876-83.
34. Dupont M, Pages JM, Lafitte D et al. Identification of an OprD homologue in Acinetobacter baumannii. J Proteome Res 2005; 4 2386-90.
35. Hong H, Patel DP, Tamm LK et al. The outer membrane protein OmpW forms an eight-stranded β-barrel with a hydrophobic channel. J Biol Chem 2006; 281: 7568-77.
36. Poole K. Outer membranes and efflux: The path to multidrug resistance in Gram-negative bacteria. Curr Pharm Biotechnol 2002; 3: 77-98.
37. Barker KF. Antibiotic resistance: A current perspective. J Clin Pharmacol 1999; 48:109-24.
38. Henderson PJF, Hoyle CK, Ward A. Efflux proteins. Biochem Soc Trans 2000; 28: 513-7.
39. Magnet S, Courvalin P, Lambert T. Resistance-nodulation-cell division-type efflux pump involved in aminoglycoside resistance in Acinetobacter baumannii strain BM4454. Antimicrob Agents Chemother 2001; 45: 3375-80.
40. Chopra I, Roberts M. Tetracycline antibiotics: Mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev 2001; 65: 232-60.
41. Martí S, Fernández-Cuenca F, Pascual A et al. Prevalence of the tetA and tetB genes as mechanisms of resistance to tetracycline and minocycline in Acinetobacter baumannii clinical isolates. Enferm Infecc Microbiol Clin 2006; 24: 77-80.
42. Guardabassi L, Dijkshoom L, Collard JM et al. Distribution and in-vitro transfer of tetracycline resistance determinants in clinical and aquatic Acinetobacter strains. J Med Microbiol 2000; 49: 929-36.
43. Marchand I, Damier-Piolle L, Courvalin P et al. Expression of the RND-type efflux pump AdeABC in Acinetobacter baumannii is regulated by the AdeRS two-component system. Antimicrob Agents Chemother 2004; 48: 3298-304.
44. Higgins PG, Wisplinghoff H, Stefanik D et al. Selection of topoisomerase mutations and overexpression of adeB mRNA transcripts during an outbreak of Acinetobacter baumannii. J Antimicrob Chemother 2004; 54: 821-3.
45. Piddock L. Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria. Clin Microbiol Rev 2006; 19: 382-402.
46. +-coupled Acinetobacter baumannii multidrug efflux pump belonging to the MATE family of transporters. Antimicrob Agents Chemother 2005; 49 4362-4.
47. Vila J, Ribera A, Marco F et al. Activity of clinafloxacin, compared with six other quinolones, against Acinetobacter baumannii clinical isolates. J Antimicrob Chemother 2002; 49: 471-7.
48. Ribera A, Ruiz J, Jimenez de Anta T et al. Effect of an efflux pump inhibitor on the MIC of nalidixic acid for Acinetobacter baumannii and Stenotrophomonas maltophilia clinical isolates. J Antimicrob Chemother 2002; 49: 697-702.